Skip to main content

Puma Biotechnology, Inc.

PBYI
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001401667

In the last 90 days, Puma Biotechnology, Inc. insiders filed 0 open-market purchases and 5 sales; 160 institutions reported holding it in 13F filings for Q2 2026, worth $313.6M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Puma Biotechnology, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of PBYI: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders120116−4
Shares34.8M32.2M−2.60M (−7.5%)
Value$319.3M$226.0M−$93.2M (−29.2%)

New holders (12)

Institutions that held Puma Biotechnology, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to PBYI in Q3 2021
InstitutionSharesValue% of portfolio
Eversept Partners, LP397,940$2.79M0.22%
Candriam Luxembourg S.C.A.–$502.0K0.00%
HSBC Holdings PLC23,284$163.0K0.00%
Marshall Wace, LLP23,276$163.0K0.00%
Man Group plc22,200$156.0K0.00%
Campbell & CO Investment Adviser LLC20,400$143.0K0.05%
Algert Global LLC18,588$130.0K0.02%
SG Americas Securities, LLC15,091$106.0K0.00%
HighVista Strategies LLC11,972$84.0K0.06%
Gyon Technologies Capital Management, LP11,464$80.0K0.02%
LPL Financial LLC10,420$73.0K0.00%
Aspire Private Capital, LLC500$4.00K0.00%

Sold out (16)

Institutions that held Puma Biotechnology, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.